Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs

References

• Chakraborty S, Shukla D, Mishra B, et al. Lipid – an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009;73(1):1–15.
   Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.
   Google Scholar
• Porter CJ, Charman WN. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev. 2001;50:S127–S147.
   Google Scholar
• Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–287.
   Google Scholar
• Pouton CW, Porter CJ. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 2008;60(6):625–637.
   Google Scholar
• Brogård M, Troedsson E, Thuresson K, et al. A new standardized lipolysis approach for characterization of emulsions and dispersions. J Colloid Interface Sci. 2007;308(2):500–507.
   Google Scholar
• Cheng Y, Xu Z, Ma M, et al. Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci. 2008;97(1):123–143.
   Google Scholar
• Cai Z, Wang Y, Zhu L-J, et al. Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab. 2010;11(2):197–207.
   Google Scholar
• Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev. 1997;25(1):103–128.
   Google Scholar
• Banerjee S, Pillai J. Lipid nanoparticle formulations for enhanced anti-tuberculosis therapy. In: Alina Maria Holban, Alexandru Mihai Grumezescu, William Andrew, (Eds). Nanoarchitectonics for smart delivery and drug targeting Amsterdam. Elsevier; 2016. p. 285–313.
   Google Scholar
• Muller R Arzneistofftrager aus festen lipidteilchen (Feste Lipidnanospharen (SLN)). Eur Patent EP 0605497 B1. 1996.
   Google Scholar
• Westesen K, Bunjes H, Koch M. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release. 1997;48(2–3):223–236.
   Google Scholar
• Chen C, Fan T, Jin Y, et al. Orally delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micelle–double emulsion method via the combined use of different solid lipids. Nanomedicine. 2013;8(7):1085–1100.
   Google Scholar
• Müller RH, Mäder K, Lippacher A, et al., 2000. Fest-flüssige (halbfeste) Lipidpartikel und Verfahren zur Herstellung hochkonzentrierter Lipidpartikeldispersionen. PCT application PCT/EP00/04565.
   Google Scholar
• Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN®, NLC®, LDC®) for oral drug delivery. Drug Dev Ind Pharm. 2008;34(12):1394–1405.
   Google Scholar
• Banerjee S, Roy S, Nath Bhaumik K, et al. Comparative study of oral lipid nanoparticle formulations (LNFs) for chemical stabilization of antitubercular drugs: physicochemical and cellular evaluation. Artif Cells Nanomed Biotechnol. 2018;46(sup1):540–558.
   Google Scholar
• Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res. 1989;6(1):40–43.
   Google Scholar
• Klassieren SM. Mechanische Verfahrenstechnik 1. Berlin, Heidelberg: Springer; 1995. p. 276–350.
   Google Scholar
• Carey MC, Small DM, Bliss CM. Lipid digestion and absorption. Annu Rev Physiol. 1983;45(1):651–677.
   Google Scholar
• Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125(1):91–97.
   Google Scholar
• Charman WN, Porter CJ, Mithani S, et al. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997;86(3):269–282.
   Google Scholar
• Charman WN. Lipids, lipophilic drugs, and oral drug delivery – some emerging concepts. J Pharm Sci. 2000;89(8):967–978.
   Google Scholar
• Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev. 2001;50(1–2):61–80.
   Google Scholar
• Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. Aaps Pharmscitech. 2011;12(1):62–76.
   Google Scholar
• Hörter D, Dressman J. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev. 2001;46(1–3):75–87.
   Google Scholar
• Winstanley P, Orme M. The effects of food on drug bioavailability. Br J Clin Pharmacol. 1989;28(6):621–628.
   Google Scholar
• Crounse RG. Human pharmacology of griseofulvin: the effect of fat intake on gastrointestinal absorption. J Invest Dermatol. 1961;37(6):529-533.
   Google Scholar
• Feinle C, Rades T, Otto B, et al. Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans. Gastroenterology. 2001;120(5):1100–1107.
   Google Scholar
• Ladas S, Isaacs P, Murphy G, et al. Comparison of the effects of medium and long chain triglyceride containing liquid meals on gall bladder and small intestinal function in normal man. Gut. 1984;25(4):405–411.
   Google Scholar
• Dahan A, Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm. 2007;67(1):96–105.
   Google Scholar
• Wagner D, Spahn-Langguth H, Hanafy A, et al. Intestinal drug efflux: formulation and food effects. Adv Drug Deliv Rev. 2001;50:S13–S31.
   Google Scholar
• Schmid-Schönbein GW. The second valve system in lymphatics. Lymphat Res Biol. 2003;1(1):25–31.
   Google Scholar
• Roger E, Lagarce F, Garcion E, et al. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009;140(2):174–181.
   Google Scholar
• Li C, Fleisher D, Li L, et al. Regional‐dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs. J Pharm Sci. 2001;90(1):47–57.
   Google Scholar
• Martinez M, Amidon G, Clarke L, et al. Applying the biopharmaceutics classification system to veterinary pharmaceutical products: part ii. Physiological considerations. Adv Drug Deliv Rev. 2002;54(6):825–850.
   Google Scholar
• Sanjula B, Shah FM, Javed A, et al. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target. 2009;17(3):249–256.
   Google Scholar
• Khoo S-M, Shackleford DM, Porter CJ, et al. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm Res. 2003;20(9):1460–1465.
   Google Scholar
• Gershkovich P, Hoffman A. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. Eur J Pharm Sci. 2007;32(1):24–32.
   Google Scholar
• Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702–716.
   Google Scholar
• Ljusberg-Wahren H, Nielsen FS, Brogård M, et al. Enzymatic characterization of lipid-based drug delivery systems. Int J Pharm. 2005;298(2):328–332.
   Google Scholar
• Porter CJ, Pouton CW, Cuine JF, et al. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60(6):673–691.
   Google Scholar
• Borgström B. Importance of phospholipids, pancreatic phospholipase A2, and fatty acid for the digestion of dietary fat: in vitro experiments with the porcine enzymes. Gastroenterology. 1980;78(5):954–962.
   Google Scholar
• Bernbäck S, Bläckberg L, Hernell O. Fatty acids generated by gastric lipase promote human milk triacylglycerol digestion by pancreatic colipase-dependent lipase. Biochim Biophys Acta (BBA)-Lipids Lipid Metab. 1989;1001(3):286–293.
   Google Scholar
• Embleton JK, Pouton CW. Structure and function of gastro-intestinal lipases. Adv Drug Deliv Rev. 1997;25(1):15–32.
   Google Scholar
• Kozlov M, Helfrich W. Effects of a cosurfactant on the stretching and bending elasticities of a surfactant monolayer. Langmuir. 1992;8(11):2792–2797.
   Google Scholar
• Ollivon M, Eidelman O, Blumenthal R, et al. Micelle-vesicle transition of egg phosphatidylcholine and octylglucoside. Biochemistry. 1988;27(5):1695–1703.
   Google Scholar
• Paternostre MT, Roux M, Rigaud JL. Mechanisms of membrane protein insertion into liposomes during reconstitution procedures involving the use of detergents. 1. Solubilization of large unilamellar liposomes (prepared by reverse-phase evaporation) by triton X-100, octyl glucoside, and sodium cholate. Biochemistry. 1988;27(8):2668–2677.
   Google Scholar
• Borel P, Pasquier B, Armand M, et al. Processing of vitamin A and E in the human gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2001;280(1):G95–G103.
   Google Scholar
• Fatouros DG, Bergenstahl B, Mullertz A. Morphological observations on a lipid-based drug delivery system during in vitro digestion. Eur J Pharm Sci. 2007;31(2):85–94.
   Google Scholar
• Hernell O, Staggers JE, Carey MC. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry. 1990;29(8):2041–2056.
   Google Scholar
• Kossena GA, Charman WN, Wilson CG, et al. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res. 2007;24(11):2084–2096.
   Google Scholar
• Kossena GA, Boyd BJ, Porter CJ, et al. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water‐soluble drugs. J Pharm Sci. 2003;92(3):634–648.
   Google Scholar
• Stremmel W. Uptake of fatty acids by jejunal mucosal cells is mediated by a fatty acid binding membrane protein. J Clin Invest. 1988;82(6):2001–2010.
   Google Scholar
• Charman WN, Porter CJ. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Deliv Rev. 1996;19(2):149–169.
   Google Scholar
• Harrison EH. Mechanisms of digestion and absorption of dietary vitamin A. Annu Rev Nutr. 2005;25:87–103.
   Google Scholar
• Ichihashi T, Kinoshita H, Takagishi Y, et al. Effect of oily vehicles on absorption of mepitiostane by the lymphatic system in rats. J Pharm Pharmacol. 1992;44(7):560–564.
   Google Scholar
• Myers R, Stella V. Factors affecting the lymphatic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug: comparison to DDT and hexachlorobenzene. Int J Pharm. 1992;80(1–3):51–62.
   Google Scholar
• Bummer PM. Physical chemical considerations of lipid-based oral drug delivery – solid lipid nanoparticles. Crit Rev Ther Drug. 2004;21:1–19.
   Google Scholar
• Charman W, Stella V. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986;34(1–2):175–178.
   Google Scholar
• Thomson A, Keelan M, Garg M, et al. Intestinal aspects of lipid absorption: in review. Can J Physiol Pharmacol. 1989;67(3):179–191.
   Google Scholar
• Banerjee S, Roy S, Bhaumik KN, et al. Mechanisms of the effectiveness of lipid nanoparticle formulations loaded with anti-tubercular drugs combinations toward overcoming drug bioavailability in tuberculosis. J Drug Targeting. 2019. DOI:10.1080/1061186X.2019.1613409
   Google Scholar
• Hu L, Jia H, Luo Z, et al. Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles. Die Pharmazie- Int J Pharm Sci. 2010;65(2):110–113.
   Google Scholar
• Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res. 2010;20(4):286–296.
   Google Scholar
• Jain AS, Shah SM, Nagarsenker MS, et al. Lipid colloidal carriers for improvement of anticancer activity of orally delivered quercetin: formulation, characterization and establishing in vitro–in vivo advantage. J Biomed Nanotechnol. 2013;9(7):1230–1240.
   Google Scholar
• Washington C. Evaluation of non-sink dialysis methods for the measurement of drug release from colloids: effects of drug partition. Int J Pharm. 1989;56(1):71–74.
   Google Scholar
• Washington C. Drug release from microdisperse systems: a critical review. Int J Pharm. 1990;58(1):1–12.
   Google Scholar
• Shen J, Burgess DJ. In vitro dissolution testing strategies for nanoparticulate drug delivery systems: recent developments and challenges. Drug Deliv Transl Res. 2013;3(5):409–415.
   Google Scholar
• Levy M, Benita S. Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int J Pharm. 1990;66:29–37.
   Google Scholar
• Larsen A, Holm R, Pedersen ML, et al. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. Pharm Res. 2008;25(12):2769–2777.
   Google Scholar
• Larsen AT, Sassene P, Müllertz A. In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems. Int J Pharm. 2011;417(1–2):245–255.
   Google Scholar
• Zangenberg NH, Müllertz A, Kristensen HG, et al. A dynamic in vitro lipolysis model: II: evaluation of the model. Eur J Pharm Sci. 2001;14(3):237–244.
   Google Scholar
• Antunes F, Andrade F, Ferreira D, et al. Models to predict intestinal absorption of therapeutic peptides and proteins. Curr Drug Metab. 2013;14(1):4–20.
   Google Scholar
• Balimane PV, Chong S. Cell culture-based models for intestinal permeability: a critique. Drug Discov Today. 2005;10(5):335–343.
   Google Scholar
• Barthe L, Bessouet M, Woodley J, et al. The improved everted gut sac: a simple method to study intestinal P-glycoprotein. Int J Pharm. 1998;173(1–2):255–258.
   Google Scholar
• Ruan L-P, Chen S, Yu B-Y, et al. Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model. Eur J Med Chem. 2006;41(5):605–610.
   Google Scholar
• Rizvi SZH, Shah FA, Khan N, et al. Simvastatin-loaded solid lipid nanoparticles for enhanced antihyperlipidemic activity in hyperlipidemia animal model. Int J Pharm. 2019;560:136–143.
   Google Scholar
• Souto EB, Doktorovova S, Campos JR, et al. Surface-tailored anti-HER2/neu-solid lipid nanoparticles for site-specific targeting MCF-7 and BT-474 breast cancer cells. Eur J Pharm Sci. 2019;128:27–35.
   Google Scholar
• Din F,A, UllahShah K, Rehman Z. Development, in-vitro and in-vivo evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product. J Drug Delivery Sci Technol. 2019;51:583–590.
   Google Scholar
• Patel MH, Mundada VP, Sawant KK. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization, in vitrocharacterization, cell line studies and in vivo efficacy in schizophrenia. Drug Dev Ind Pharm. 2019. DOI:10.1080/03639045.2019.1593434
   Google Scholar
• El-Say KM, Hosny KM. Optimization of carvedilol solid lipid nanoparticles: an approach to control the release and enhance the oral bioavailability on rabbits. PLoS One. 2018;13(8):e0203405.
   Google Scholar
• Shazly GA, Alshehri S, Ibrahim MA, et al. Development of Domperidone Solid Lipid Nanoparticles: in Vitro and In Vivo Characterization. AAPS PharmSciTech. 2018;19(4):1712–1719.
   Google Scholar
• Yining X, Zheng Y, Lei W, et al. Novel solid lipid nanoparticle with endosomal escape function for oral delivery of insulin. ACS Appl Mater Interfaces. 2018;10(11):9315–9324.
   Google Scholar
• Baek JS, Cho CW. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Eur J Pharm Biopharm. 2017;117:132–140.
   Google Scholar
• Kim JT, Barua S, Kim H, et al. Absorption study of Genistein using solid lipid microparticles and nanoparticles: control of oral bioavailability by particle sizes. Biomol Ther (Seoul). 2017;25(4):452–459.
   Google Scholar
• Qureshi OS, Kim HS, Zeb A, et al. Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration. J Microencapsul. 2017 May;34(3):250–261.
   Google Scholar
• Gonçalves L, Maestrelli F, Mannelli LDC, et al. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide. Eur J Pharm Biopharm. 2016;102:41–50.
   Google Scholar
• Ramalingam P, Ko YT. Improved oral delivery of resveratrol from N-trimethyl chitosan-g-palmitic acid surface-modified solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2016;139:52–61.
   Google Scholar
• Guada M, Lana H, Gil AG, et al. Cyclosporine A lipid nanoparticles for oral administration: pharmacodynamics and safety evaluation. Eur J Pharm Biopharm. 2016;101:112–118.
   Google Scholar
• Liu Y, Salituro GM, Lee KJ, et al. Modulating drug release and enhancing the oral bioavailability of Torcetrapib with solid lipid dispersion formulations. AAPS Pharm Sci Tech. 2015;16(5):1091–1100.
   Google Scholar
• Shangguan M, Qi J, Lu Y, et al. Comparison of the oral bioavailability of silymarin-loaded lipid nanoparticles with their artificial lipolysate counterparts: implications on the contribution of integral structure. Int J Pharm. 2015. 15. 489(1–2):195–202.
   Google Scholar
• Dwivedi P, Khatik R, Khandelwal K, et al. Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm. 2014;466(1–2):321–327.
   Google Scholar
• Singh A, Ahmad I, Akhter S, et al. Nanocarrier based formulation of Thymoquinone improves oral delivery: stability assessment, in vitro and in vivo studies. Colloids Surf B Biointerfaces. 2013;102:822–832.
   Google Scholar
• Bhandari R, Kaur IP. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm. 2013;441(1–2):202–212.
   Google Scholar
• Singh H, Bhandari R, Kaur IP. Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH. Int J Pharm. 2013;446(1–2):106–111.
   Google Scholar
• Venishetty VK, Chede R, Komuravelli R, et al. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surf B Biointerfaces. 2012;95:1–9.
   Google Scholar
• Zhang Z, Gao F, Bu H, et al. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine. 2012;8(5):740–747.
   Google Scholar
• Chalikwar SS, Belgamwar VS, Talele VR, et al. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloids Surf B Biointerfaces. 2012;97:109–116.
   Google Scholar
• Xie S, Zhu L, Dong Z, et al. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces. 2011;83(2):382–387.
   Google Scholar
• Liu Y, Wang P, Sun C, et al. Bioadhesion and enhanced bioavailability by wheat germ agglutinin-grafted lipid nanoparticles for oral delivery of poorly water-soluble drug bufalin. Int J Pharm. 2011;419(1–2):260–265.
   Google Scholar
• Pandita D, Ahuja A, Lather V, et al. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. Aaps Pharmscitech. 2011;12(2):712–722.
   Google Scholar
• Silva A, González-Mira E, García M, et al. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces. 2011;86(1):158–165.
   Google Scholar
• Tsai M-J, Huang Y-B, Wu P-C, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci. 2011;100(2):547–557.
   Google Scholar
• Kakkar V, Singh S, Singla D, et al. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res. 2011;55(3):495–503.
   Google Scholar
• Aji Alex MR, Chacko AJ, Jose S, et al. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42:11–18.
   Google Scholar
• Hu L, Xing Q, Meng J, et al. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. Aaps Pharmscitech. 2010;11(2):582–587.
   Google Scholar
• Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res. 2010;20(2):115–123.
   Google Scholar
• Xie S, Pan B, Wang M, et al. Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomedicine. 2010;5(5):693–701.
   Google Scholar
• Zhang Z, Bu H, Gao Z, et al. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int J Pharm. 2010;394(1–2):147–153.
   Google Scholar
• Zhang Z, Lv H, Zhou J. Novel solid lipid nanoparticles as carriers for oral administration of insulin. Die Pharmazie- Int J Pharm Sci. 2009;64(9):574–578.
   Google Scholar
• Li H, Zhao X, Ma Y, et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release. 2009;133(3):238–244.
   Google Scholar
• Hanafy A, Spahn-Langguth H, Vergnault G, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev. 2007;59(6):419–426.
   Google Scholar
• Suresh G, Manjunath K, Venkateswarlu V, et al. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. Aaps Pharmscitech. 2007;8(1):E162–E170.
   Google Scholar
• Müller R, Runge S, Ravelli V, et al. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm. 2006;317(1):82–89.
   Google Scholar
• Luo Y, Chen D, Ren L, et al. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release. 2006;114(1):53–59.
   Google Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 2005;107(2):215–228.
   Google Scholar
• Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004;56(12):1527–1535.
   Google Scholar
• Teng Z, Yu M, Ding Y, et al. Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability. Int J Nanomedicine. 2019;14:119–133.
   Google Scholar
• Khan AA, Mudassir J, Akhtar S, et al. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: statistical optimization, in vitro and in vivo evaluations. Pharmaceutics. 2019;11:97.
   Google Scholar
• Harshita, Barkat MA, Rizwanullah M, et al. Paclitaxel-loaded nanolipidic carriers with improved oral bioavailability and anticancer activity against human liver carcinoma. AAPS Pharm Sci Tech. 2019;20:87.
   Google Scholar
• Elmowafy M, Shalaby K, Badran MM, et al. Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation. Int J Pharm. 2018 Oct 25;550(1–2):359–371.
   Google Scholar
• Li J, Yang M, Xu W. Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model. Drug Des Devel Ther. 2018;12:2241–2248.
   Google Scholar
• Wei Q, Yang Q, Wang Q, et al. Formulation, characterization, and pharmacokinetic studies of 6-gingerol-loaded nanostructured lipid carriers. AAPS Pharm Sci Tech. 2018;19:3661.
   Google Scholar
• Dudhipala N, Janga KY, Gorre T. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artif Cells Nanomed Biotechnol. 2018;46(sup 2):616–625.
   Google Scholar
• Tian C, Asghar S, Wu Y, et al. N-acetylL-cysteine functionalized nanostructured lipid carrier for improving oral bioavailability of curcumin: preparation, invitro and in-vivo evaluations. Drug Deliv. 2017;24(1):1605–1616.
   Google Scholar
• Yin J, Hou Y, Yin Y, et al. Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect. Int J Nanomedicine. 2017;12:8671–8680.
   Google Scholar
• Yu Q, Hu X, Ma Y, et al. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus. Drug Deliv. 2016;23(4):1469–1475.
   Google Scholar
• Shah NV, Seth AK, Balaraman R, et al. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. J Adv Res. 2016;7(3):423–434.
   Google Scholar
• Shangguan M, Qi J, Lu Y, et al. Comparison of the oral bioavailability of silymarin-loaded lipid nanoparticles with their artificial lipolysate counterparts: implications on the contribution of integral structure. Int J Pharm. 2015. 15. 489(1–2):195–202.
   Google Scholar
• Zhou J, Zhou D. Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers. Drug Des Devel Ther. 2015;9: 5269–5275. Published 2015 Sep 18.
   Google Scholar
• Luan J, Zhang D, Hao L, et al. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers. Colloids Surf B Biointerfaces. 2014;114:255–260.
   Google Scholar
• Beloqui A, Solinís MÁ, Delgado A, et al. Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. J Microencapsul. 2014;31(1):1–8.
   Google Scholar
• Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. Eur J Pharm Biopharm. 2014;88(1):160–168.
   Google Scholar
• Beloqui A, Solinís MÁ, Gascón AR, et al. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013;166(2):115–123.
   Google Scholar
• Mendes A, Silva A, Catita J, et al. Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: improving antifungal activity. Colloids Surf B Biointerfaces. 2013;111:755–763.
   Google Scholar
• Jain AS, Shah SM, Nagarsenker MS, et al. Lipid colloidal carriers for improvement of anticancer activity of orally delivered quercetin: formulation, characterization and establishing in vitro-in vivo advantage. J Biomed Nanotechnol. 2013;9:1230–1240.
   Google Scholar
• Abdelwahab SI, Sheikh BY, Taha MME, et al. Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. Int J Nanomedicine. 2013;8:2163.
   Google Scholar
• Thatipamula R, Palem C, Gannu R, et al. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru. 2011;19(1):23.
   Google Scholar
• Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. 2011;415(1–2):232–243.
   Google Scholar
• Muchow M, Maincent P, Müller R, et al. Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. Drug Dev Ind Pharm. 2011;37(1):8–14.
   Google Scholar
• Zhang T, Chen J, Zhang Y, et al. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci. 2011;43(3):174–179.
   Google Scholar
• Chen -C-C, Tsai T-H, Huang Z-R, et al. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm. 2010;74(3):474–482.
   Google Scholar
• Zhuang C-Y, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394(1–2):179–185.
   Google Scholar
• Banerjee S, Kundu A. Lipid-drug conjugates: a potential nanocarrier system for oral drug delivery applications. DARU J Pharma Sci. 2018;26:65–75.
   Google Scholar
• Ding Y, Nielsen KA, Nielsen BP, et al. Lipid-drug-conjugate (LDC) solid lipid nanoparticles (SLN) for the delivery of nicotine to the oral cavity – optimization of nicotine loading efficiency. Eur J Pharm Biopharm. 2018;128:10–17.
   Google Scholar
• Ma Y, He H, Xia F, et al. In vivo fate of lipid-silybin conjugate nanoparticles: implications on enhanced oral bioavailability. Nanomedicine. 2017;13(8):2643–2654.
   Google Scholar
• Soni K, Mujtaba A, Kohli K. Lipid drug conjugate nanoparticle as a potential nanocarrier for the oral delivery of pemetrexed diacid: formulation design, characterization, ex vivo, and in vivo assessment. Int J Biol Macromol. 2017;103:139–151.
   Google Scholar
• Neupane YR, Sabir M, Ahmad N, et al. Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine: ex vivo gut permeation studies. Nanotechnology. 2013;24(41):415102.
   Google Scholar
• Vadlapudi AD, Vadlapatla RK, Kwatra D, et al. Targeted lipid based drug conjugates: a novel strategy for drug delivery. Int J Pharm. 2012;434(1–2):315–324.
   Google Scholar
• Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289.
   Google Scholar
• Etheridge ML, Campbell SA, Erdman AG, et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9(1):1–14.
   Google Scholar
• Hafner A, Lovric J, Lakos GP, et al. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine. 2014;9:1005–1023.
   Google Scholar
• Musazzi UM, Marini V, Casiraghi A,P, et al. Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials? Drug Discov Today. 2017;22(6):870–882.
   Google Scholar
• Battaglia L, Ugazio E. Lipid nano- and microparticles: an overview of patent-related research. J Nanomater. 2019:1–22 Article ID 2834941. 10.1155/2019/2834941
   Google Scholar
• Cegla U. Long-term therapy over 2 years with ambroxol (Mucosolvan) retard capsules in patients with chronic bronchitis. Results of a double-blind study of 180 patients. Praxis Und Klinik Der Pneumologie. 1988;42(9):715.
   Google Scholar